Editorial & Columns Defying Third Generation Curse: Indian Companies with roots in Ayurved October 9, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns GST 2.0: Dissecting Impact on Consumption, Household Debt and Savings October 1, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Swadeshi-Inspired Indian Pharmaceutical Industry September 25, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Surge in Employment and Salary in Pharma Companies September 18, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25: Mapping R&D Expenditure of Pharma Companies September 11, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns GST Dose for Healthcare Sector September 4, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Price Capping on Cardiovascular Drugs in India: Impact Assessment August 26, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns FY25 Review: Capital Efficiency of Pharmaceutical Companies in India August 20, 2025 | Dr. Anil Kumar Angrish, Robin Kumar | No Comments | More
Editorial & Columns Market Access- Global Footprint of Indian Pharma Companies August 12, 2025 | Dr. Anil Kumar Angrish | No Comments | More
Editorial & Columns Drug Price Control on Anti-Diabetic formulations in India August 6, 2025 | Dr. Anil Kumar Angrish | No Comments | More